Welcome to our dedicated page for Eledon Pharmaceuticals SEC filings (Ticker: ELDN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Eledon Pharmaceuticals SEC filings document the governance, financing and clinical-development disclosures of a clinical-stage biotechnology issuer centered on tegoprubart. Proxy materials cover shareholder voting matters, board and compensation governance, equity awards and executive compensation disclosures.
Material-event filings report operating results and financial condition, Regulation FD clinical updates, presentations and press-release exhibits related to tegoprubart programs in transplantation. The filing record also includes disclosure categories tied to material agreements, capital structure, shareholder matters and clinical or regulatory developments for the company’s anti-CD40L development strategy.
Eledon Pharmaceuticals: Schedule 13G/A filing reporting aggregated beneficial ownership by Biotechnology Value Fund group. As of the close of business on March 31, 2026, the Reporting Persons and a Partners managed account hold convertible securities and warrants that, subject to multiple 9.99% ownership blockers, translate into convertible and exercisable positions described below.
The filing lists aggregate holdings including 5,382,084 Shares beneficially owned by BVF, 2,057,090 Shares by BVF2, and various convertible instruments: 4,419.93 shares of Series X Preferred (convertible into 245,552 Shares), 87,607.152 shares of Series X1 Preferred (convertible into 4,867,067 Shares), 15,247,782 Pre-Funded Warrants (exercisable into 15,247,782 Shares), and 5,844,153 Tranche A Warrants. The filing explains conversion/exercise blockers that currently limit conversion or exercise into Shares.
Eledon Pharmaceuticals reports results for the quarter ended March 31, 2026, highlighting continued investment in its lead antibody tegoprubart for transplantation and ALS. The company posted a net loss of $39.0 million, compared with $6.5 million a year earlier, largely driven by a non-cash $19.0 million increase in warrant liabilities.
Operating expenses rose to $21.2 million, mainly from higher research and development spending of $17.2 million linked to kidney transplant programs and manufacturing. Cash used in operating activities was $22.6 million. Eledon ended the quarter with $111.1 million in cash, cash equivalents and short-term investments and working capital of $100.1 million, and expects these resources to fund planned operations for at least 12 months.
The balance sheet reflects $32.4 million of in-process R&D from the Anelixis acquisition and $30.4 million of warrant liabilities measured at fair value. Management reiterates that additional capital will ultimately be needed to complete development of tegoprubart, and the risk factor section emphasizes ongoing losses, funding needs, clinical and regulatory uncertainties, and competitive pressures typical for a clinical-stage biotech.
Eledon Pharmaceuticals reported first quarter 2026 results and progress for its lead antibody tegoprubart. In an investigator-led islet transplant study, all 10 patients who were more than four weeks post-transplant achieved 100% insulin independence with no graft rejection or typical tacrolimus-related toxicities. Tegoprubart also received FDA Orphan Drug designation for preventing allograft rejection in liver transplantation.
In kidney transplantation, 24‑month Phase 1b extension data in eight patients showed no biopsy‑proven acute rejection, graft loss, death, new-onset diabetes, or de novo donor‑specific antibodies, and mean eGFR improved from 67.0 to 74.2 mL/min/1.73 m². Cash, cash equivalents and short‑term investments were $111.1 million as of March 31, 2026, which the company believes will fund operations into the second quarter of 2027.
R&D expenses were $17.2 million versus $13.5 million a year earlier, while G&A was $4.0 million versus $4.4 million. Net loss was $39.0 million, or $0.33 per common share, compared with $6.5 million, or $0.08 per share, mainly due to a $19.0 million non‑cash loss from warrant liabilities versus a $10.1 million non‑cash gain in 2025; excluding these, net loss was $20.1 million versus $16.6 million.
Eledon Pharmaceuticals, Inc. filed a shelf registration on that permits offers of up to $500,000,000 of common stock, preferred stock, debt securities, warrants and/or units. The filing also includes an at-the-market sales agreement to sell up to $75,000,000 of common stock through Guggenheim Securities.
The prospectus describes that sales under the sales agreement are at market prices or negotiated prices and that net proceeds will be used for working capital and general corporate purposes. The company reported 75,430,033 shares of common stock outstanding as of December 31, 2025, and the last reported sale price was $3.64 per share on April 30, 2026. The filing reiterates clinical-program details for tegoprubart and discloses that ALS development requires additional funding.
Eledon Pharmaceuticals is asking stockholders to approve three items at its 2026 annual meeting. Investors will vote on electing three Class III directors — David‑Alexandre C. Gros, M.D., Jan Hillson, M.D., and James Robinson — to terms running until the 2029 meeting.
They will also consider an amendment to increase authorized common shares from 300,000,000 to 450,000,000, which would give the company more capacity to issue equity in the future. A third proposal seeks ratification of Deloitte & Touche LLP as independent auditor for the year ending December 31, 2026.
The proxy details governance practices, board committee structures and director independence, and outlines director and executive pay. As of the April 20, 2026 record date, 77,187,823 common shares were outstanding and entitled to vote at the June 18, 2026 in‑person meeting in Irvine, California.
BlackRock, Inc. reported beneficial ownership of 4,380,857 shares of Eledon Pharmaceuticals, Inc. common stock, equal to 5.8% of the class as of 03/31/2026. The Schedule 13G shows BlackRock holds sole dispositive power for 4,380,857 shares and sole voting power for 4,324,348 shares. The filing notes that various persons may have rights to dividends or sale proceeds and that no single outside person holds more than 5% of the class.
Eledon Pharmaceuticals will hold its 2026 Annual Meeting of Stockholders on June 18, 2026 at its Irvine, California office to elect three Class III directors, seek stockholder approval to increase authorized common shares from 300,000,000 to 450,000,000, and ratify Deloitte & Touche LLP as auditor. The Board set the record date as April 20, 2026. Proxy materials and the 2025 Annual Report are available at proxydocs.com/ELDN. The Proxy Statement describes director nominees, governance policies, committee composition, non-employee director pay, named executive officer compensation, related-party financings involving certain institutional holders, and procedures for voting in person, by phone, internet, or mail.
Eledon Pharmaceuticals Inc amendment to a Schedule 13G/A shows The Vanguard Group reports 0 shares beneficially owned, representing 0% of the common stock. The filing explains an internal realignment on January 12, 2026 that led certain Vanguard subsidiaries to report separately.